Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
XBiotech Inc. (XBIT)
USD2.29
+0.00 (+0.44%)
US NASDAQ Healthcare Biotechnology
Address
5217 Winnebago Lane 78744
Austin, TX, US
Austin, TX, US
CEO
Sushma Shivaswamy
Website
xbiotech.com
IPO
2015-04-15
CIK 1626878 ISIN CA98400H1029
Description
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.29
+0.00 (+0.44%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
27.8K
Beta
0.84
Float Shares
19.32M
Free Float %
63.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +2.88% | +2.04% | -5.30% | +4.60% | -13.19% | -25.15% | -85.39% | -82.14% | -89.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
2.29
DCF (Unlevered)
4.08
+78.3%
DCF (Levered)
4.12
+79.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
8.09
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-18.3% Q1'26: +50.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-376.3% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|
| Revenue |
44.00M
est: 28.00M (+57.1%)
|
18.39M
est: 28.00M (-34.3%)
|
—
est: 150.00M (-100.0%)
|
—
|
| EBITDA |
-16.04M
est: -2.04M (-685.7%)
|
-22.43M
est: -2.04M (-999.0%)
|
-22.57M
est: -10.94M (-106.4%)
|
-36.01M
|
| EBIT |
-18.28M
est: -2.33M (-685.7%)
|
-25.08M
est: -2.33M (-978.2%)
|
-24.31M
est: -12.46M (-95.1%)
|
-37.76M
|
| Net Income |
-11.22M
est: 5.79M (-293.9%)
|
-17.41M
est: 3.96M (-539.8%)
|
-24.56M
est: 88.03M (-127.9%)
|
-38.53M
est: -52.70M (+26.9%)
|
| SGA |
18.20M
est: 25.18M (-27.7%)
|
9.39M
est: 25.18M (-62.7%)
|
4.66M
est: 134.89M (-96.5%)
|
4.71M
|
| EPS |
-0.36
est: 0.19 (-289.5%)
|
-0.58
est: 0.13 (-546.2%)
|
-0.81
est: 2.89 (-128.0%)
|
-1.26
est: -1.73 (+27.2%)
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-39.92M
OE per share TTM
-1.31
Owner's Yield
-53.01%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
271.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
40
Total invested
5.49M
Insider transactions (90d)
0
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | John Simard | 5.19M | 16.33% | 5.19M | — | 5.19M | — | IN | Canada | 2023-02-10 | ↗ |
| 2 | Thomas Gut | 3.91M | 12.86% | 3.91M | — | 3.91M | — | IN | Switzerland | 2023-02-10 | ↗ |
| 3 | Page 2 of 5 Pages | 3.58M | 9.99% | 3.58M | — | 3.58M | — | OO | Principality Liechtenstein | 2019-02-07 | ↗ |
| 4 | W. Thorpe McKenzie | 3.04M | 9.87% | 2.93M | 106.3K | 2.93M | 106.3K | IN | USA | 2023-02-10 | ↗ |
| 5 | 2 | 1.91M | 5.88% | 1.91M | — | 1.91M | — | OO | Principality of Liechtenstein | 2016-12-16 | ↗ |
| 6 | Lombard International Assurance S.A. | 1.11M | 3.66% | 1.11M | — | 1.11M | — | FI | Luxembourg | 2023-01-12 | ↗ |
| 7 | Fondation | 110.3K | 0.27% | 110.3K | — | 110.3K | — | OO | — | 2020-02-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
40
-5 vs prev Q
New positions
5
Closed positions
10
Increased
13
Reduced
15
Put/Call ratio
0.00
Calls held
18.4K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 11.8K +11.8K (+100.0%) | 28.19M +28.2M (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD2.39 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 299.6K -519.7K (-63.4%) | 715.9K -1.5M (-67.1%) | 0.98% -1.705 pp | 0.00% +0.000 pp | USD11.11 -78.5% | 43 qtrs — |
| 3 | BLACKROCK, INC. | 288.6K -13.8K (-4.5%) | 689.8K -114.5K (-14.2%) | 0.95% -0.045 pp | 0.00% +0.000 pp | USD7.60 -68.6% | 6 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 221.1K -742.0 (-0.3%) | 528.7K -61.7K (-10.5%) | 0.73% -0.002 pp | 0.00% +0.000 pp | USD7.76 -69.2% | 42 qtrs — |
| 5 | RBF CAPITAL, LLC | 198.5K -1.5K (-0.7%) | 474.4K -57.6K (-10.8%) | 0.65% -0.005 pp | 0.02% -0.003 pp | USD2.97 -19.5% | 3 qtrs — |
| 6 | AMERIPRISE FINANCIAL INC | 186.8K +186.8K (+100.0%) | 446.4K +446.4K (+100.0%) | 0.61% +0.613 pp | 0.00% +0.000 pp | USD2.39 +0.0% | 1 qtrs NEW |
| 7 | MORGAN STANLEY | 163.4K +42.0K (+34.6%) | 390.6K +67.5K (+20.9%) | 0.54% +0.138 pp | 0.00% +0.000 pp | USD4.63 -48.4% | 28 qtrs — |
| 8 | MILLENNIUM MANAGEMENT LLC | 135.4K -280.9K (-67.5%) | 323.7K -783.8K (-70.8%) | 0.44% -0.921 pp | 0.00% 0.000 pp | USD3.45 -30.7% | 20 qtrs — |
| 9 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 89.5K +30.0K (+50.4%) | 214.0K +55.6K (+35.1%) | 0.29% +0.098 pp | 0.00% +0.001 pp | USD3.72 -35.8% | 15 qtrs — |
| 10 | NORTHERN TRUST CORP | 76.4K -5.2K (-6.4%) | 182.7K -34.4K (-15.9%) | 0.25% -0.017 pp | 0.00% +0.000 pp | USD7.78 -69.3% | 42 qtrs — |
| 11 | STATE STREET CORP | 73.0K +5.7K (+8.5%) | 174.5K -4.6K (-2.5%) | 0.24% +0.019 pp | 0.00% +0.000 pp | USD6.87 -65.2% | 43 qtrs — |
| 12 | JANE STREET GROUP, LLC | 69.7K +14.0K (+25.1%) | 166.7K +18.3K (+12.4%) | 0.23% +0.046 pp | 0.00% +0.000 pp | USD2.72 -12.1% | 3 qtrs — |
| 13 | SQUAREPOINT OPS LLC | 64.0K +1.8K (+3.0%) | 153.0K -12.4K (-7.5%) | 0.21% +0.006 pp | 0.00% +0.000 pp | USD2.84 -15.8% | 3 qtrs — |
| 14 | EMPOWERED FUNDS, LLC | 59.5K +— (+0.0%) | 142.3K -16.1K (-10.2%) | 0.20% +0.000 pp | 0.00% -0.001 pp | USD5.72 -58.2% | 11 qtrs — |
| 15 | DIMENSIONAL FUND ADVISORS LP | 50.7K -13.6K (-21.2%) | 121.0K -50.1K (-29.3%) | 0.17% -0.045 pp | 0.00% +0.000 pp | USD8.84 -73.0% | 35 qtrs — |
| 16 | BANK OF NEW YORK MELLON CORP | 48.5K +— (+0.0%) | 115.8K -13.1K (-10.2%) | 0.16% +0.000 pp | 0.00% +0.000 pp | USD8.11 -70.5% | 43 qtrs — |
| 17 | BANK OF AMERICA CORP /DE/ | 35.9K -11.5K (-24.3%) | 85.8K -40.3K (-31.9%) | 0.12% -0.038 pp | 0.00% +0.000 pp | USD3.65 -34.5% | 43 qtrs — |
| 18 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 30.2K -5.8K (-16.1%) | 72.2K -23.6K (-24.6%) | 0.10% -0.019 pp | 0.00% 0.000 pp | USD6.40 -62.7% | 16 qtrs — |
| 19 | BNP PARIBAS ARBITRAGE, SNC | 26.9K +6.3K (+30.3%) | 64.2K +9.4K (+17.1%) | 0.09% +0.021 pp | 0.00% +0.000 pp | USD5.31 -55.0% | 42 qtrs — |
| 20 | NATIONAL BANK OF CANADA /FI/ | 25.0K +— (+0.0%) | 58.8K -7.3K (-11.0%) | 0.08% +0.000 pp | 0.00% +0.000 pp | USD5.01 -52.3% | 9 qtrs — |
| 21 | XTX TOPCO LTD | 21.7K +6.6K (+44.1%) | 51.9K +11.8K (+29.5%) | 0.07% +0.022 pp | 0.00% -0.001 pp | USD2.79 -14.3% | 3 qtrs — |
| 22 | QUBE RESEARCH & TECHNOLOGIES LTD | 20.6K -9.7K (-32.0%) | 49.3K -31.4K (-38.9%) | 0.07% -0.032 pp | 0.00% +0.000 pp | USD2.97 -19.5% | 3 qtrs — |
| 23 | AMERICAN CENTURY COMPANIES INC | 18.9K +— (+0.0%) | 45.1K -5.1K (-10.1%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD6.45 -62.9% | 7 qtrs — |
| 24 | CITADEL ADVISORS LLC | 18.4K +18.4K (+100.0%) | 44.0K +44.0K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.000 pp | USD2.39 +0.0% | 1 qtrs NEW |
| 25 | GOLDMAN SACHS GROUP INC | 16.8K -8.2K (-32.7%) | 40.2K -26.3K (-39.5%) | 0.06% -0.027 pp | 0.00% +0.000 pp | USD4.59 -47.9% | 8 qtrs — |
| 26 | TWO SIGMA ADVISERS, LP | 16.3K +— (+0.0%) | 39.0K -4.4K (-10.2%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD3.24 -26.2% | 4 qtrs — |
| 27 | PERSISTENT ASSET PARTNERS LTD | 13.6K +13.6K (+100.0%) | 32.4K +32.4K (+100.0%) | 0.04% +0.045 pp | 0.01% +0.015 pp | USD2.39 +0.0% | 1 qtrs NEW |
| 28 | THOMASVILLE NATIONAL BANK | 13.4K +— (+0.0%) | 31.9K -3.6K (-10.1%) | 0.04% +0.000 pp | 0.00% 0.000 pp | USD16.56 -85.6% | 21 qtrs — |
| 29 | TWO SIGMA SECURITIES, LLC | 10.4K +10.4K (+100.0%) | 24.8K +24.8K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.003 pp | USD2.39 +0.0% | 1 qtrs NEW |
| 30 | UBS GROUP AG | 5.1K -1.4K (-21.9%) | 12.1K -5.1K (-29.9%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD4.48 -46.7% | 26 qtrs — |
| 31 | JPMORGAN CHASE & CO | 1.1K -1.3K (-52.6%) | 2.7K -3.6K (-57.5%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD4.10 -41.7% | 11 qtrs — |
| 32 | RHUMBLINE ADVISERS | 928.00 +— (+0.0%) | 2.2K -251.0 (-10.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.68 -57.9% | 11 qtrs — |
| 33 | MCILRATH & ECK, LLC | 753.00 +— (+0.0%) | 1.8K -203.0 (-10.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.17 -86.1% | 20 qtrs — |
| 34 | FMR LLC | 450.00 +140.0 (+45.2%) | 1.1K +251.0 (+30.4%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD4.36 -45.2% | 16 qtrs — |
| 35 | JONES FINANCIAL COMPANIES LLLP | 370.00 +— (+0.0%) | 884.00 -115.0 (-11.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.95 -39.5% | 5 qtrs — |
| 36 | SIMPLEX TRADING, LLC | 67.00 +67.0 (+100.0%) | 160.00 +160.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.39 +0.0% | 3 qtrs — |
| 37 | LARSON FINANCIAL GROUP LLC | 21.00 +— (+0.0%) | 50.00 -6.0 (-10.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.95 -19.0% | 3 qtrs — |
| 38 | OPTIVER HOLDING B.V. | 8.00 +— (+0.0%) | 19.00 -2.0 (-9.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.63 -9.1% | 2 qtrs — |
| 39 | SBI SECURITIES CO., LTD. | 1.00 +— (+0.0%) | 2.00 -1.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 -20.3% | 5 qtrs — |
| 40 | BARCLAYS PLC | 1.00 -26.3K (-100.0%) | 2.00 -203.6K (-100.0%) | 0.00% -0.086 pp | 0.00% 0.000 pp | USD2.00 +19.5% | 7 qtrs — |
| 41 | ROYAL BANK OF CANADA | — -2.8K (-100.0%) | — -8.0K (-100.0%) | 0.00% -0.009 pp | 0.00% +0.000 pp | USD— | 43 qtrs SOLD |
| 42 | EVERSOURCE WEALTH ADVISORS, LLC | — -17.0 (-100.0%) | — -45.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 43 | HRT FINANCIAL LP | — -26.2K (-100.0%) | — -69.0K (-100.0%) | 0.00% -0.086 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 44 | CITIGROUP INC | — -12.0 (-100.0%) | — -32.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 10 qtrs SOLD |
| 45 | SRS CAPITAL ADVISORS, INC. | — -22.0 (-100.0%) | — -58.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 46 | SUNBELT SECURITIES, INC. | — -2.0 (-100.0%) | — -5.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 47 | TRUE WEALTH DESIGN, LLC | — -3.0 (-100.0%) | — -8.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 180.0K | 0.60% |
| 2 | EA Bridgeway Omni Small-Cap Value ETF BSVO | 0.01% | 100.4K | 0.47% |
| 3 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 30.3K | 0.25% |
| 4 | Vanguard Extended Market ETF VXF | 0.00% | 473.5K | 0.05% |
| 5 | Avantis U.S. Small Cap Value ETF AVUV | 0.00% | 11.2K | 0.25% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
0.42
Bearish
Buys
1
Sells
1
Shares acquired
1.03M
Shares disposed
2.47M
Cash buys
—
Cash sales
—
Net activity
-1,444,127
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-01 | Troy Tevi David | Director | A-Award | A | Director Stock Option | 56,000 | 2.64 | 147.8K | 56,000 | D | ↗ |
| 2025-10-01 | Soffer David Spencer | Director | A-Award | A | Director Stock Option | 51,000 | 2.64 | 134.6K | 51,000 | D | ↗ |
| 2025-10-01 | Rademaker Craig Evan | Director | A-Award | A | Director Stock Option | 92,104 | 2.64 | 243.2K | 92,104 | D | ↗ |
| 2025-10-01 | Kuendig Thomas Martin | Director | A-Award | A | Director Stock Option | 79,115 | 2.64 | 208.9K | 79,115 | D | ↗ |
| 2025-08-29 | Troy Tevi David | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-29 | Soffer David Spencer | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-29 | Rademaker Craig Evan | Director | — | — | Common Stock | 0 | 0.00 | — | 104,237 | I | ↗ |
| 2025-08-29 | Kuendig Thomas Martin | Director | — | — | Common Stock | 0 | 0.00 | — | 200,000 | D | ↗ |
| 2025-03-17 | SIMARD JOHN | Director / Officer / 10% Owner | A-Award | A | Stock Option | 1,026,228 | 3.52 | 3.61M | 1,896,609 | D | ↗ |
| 2025-01-31 | SIMARD JOHN | Director / Officer / 10% Owner | J-Other | D | Convertible Loan Agreement | 2,470,355 | 4.05 | 10.00M | 870,381 | D | ↗ |
| 2024-06-20 | Waldin Jan-Paul | Director | A-Award | A | Director Stock Option | 37,500 | 5.12 | 192.0K | 37,500 | — | ↗ |
| 2024-06-20 | MacAdam Donald H. | Director | A-Award | A | Director Stock Option | 37,500 | 5.12 | 192.0K | 37,500 | — | ↗ |
| 2024-06-20 | MCKENZIE W THORPE | Director / 10% Owner | A-Award | A | Director Stock Option | 37,500 | 5.12 | 192.0K | 37,500 | — | ↗ |
| 2024-06-20 | Libby Peter | Director | A-Award | A | Director Stock Option | 37,500 | 5.12 | 192.0K | 37,500 | — | ↗ |
| 2024-01-03 | SIMARD JOHN | Director / Officer / 10% Owner | P-Purchase | A | Convertible Loan Agreement | 2,470,355 | 4.05 | 10.00M | 3,840,736 | — | ↗ |
| 2023-08-10 | HU ANGELA | Officer | — | D | Employee Stock Option (right to buy) | 30,000 | 3.84 | 115.2K | 0 | — | ↗ |
| 2023-06-23 | Waldin Jan-Paul | Director | A-Award | A | Director Stock Option | 25,000 | 6.04 | 151.0K | 25,000 | — | ↗ |
| 2023-06-23 | MacAdam Donald H. | Director | A-Award | A | Director Stock Option | 25,000 | 6.04 | 151.0K | 25,000 | — | ↗ |
| 2023-06-23 | MCKENZIE W THORPE | Director / 10% Owner | A-Award | A | Director Stock Option | 25,000 | 6.04 | 151.0K | 25,000 | — | ↗ |
| 2023-06-23 | Libby Peter | Director | A-Award | A | Director Stock Option | 25,000 | 6.04 | 151.0K | 25,000 | — | ↗ |
| 2023-02-10 | SHIVASWAMY SUSHMA | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 3.84 | 384.0K | 100,000 | — | ↗ |
| 2023-02-10 | HU ANGELA | Officer | — | D | Common Stock | 0 | 0.00 | — | 25,500 | — | ↗ |
| 2022-11-19 | HU ANGELA | Officer | — | D | Employee Stock Option (right to buy) | 10,000 | 12.67 | 126.7K | 0 | — | ↗ |
| 2022-06-22 | Waldin Jan-Paul | Director | A-Award | A | Stock Option | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-22 | MacAdam Donald H. | Director | A-Award | A | Stock Option | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-22 | MCKENZIE W THORPE | Director | A-Award | A | Stock Option | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-22 | Libby Peter | Director | A-Award | A | Director Stock option | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2021-12-16 | MCKENZIE W THORPE | Director / 10% Owner | M-Exempt | A | Common Stock | 250,000 | 10.00 | 2.50M | 2,810,964 | — | ↗ |
| 2021-11-19 | SHIVASWAMY SUSHMA | Officer | A-Award | A | Stock Option | 100,000 | 12.67 | 1.27M | 100,000 | — | ↗ |
| 2021-11-19 | HAN QUEENA | Officer | A-Award | A | Stock Option | 35,000 | 12.67 | 443.5K | 35,000 | — | ↗ |
| 2021-10-18 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 33,000 | 13.07 | 431.3K | 3,823,166 | — | ↗ |
| 2021-10-15 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 17,000 | 13.32 | 226.5K | 3,856,166 | — | ↗ |
| 2021-10-14 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 21,125 | 12.90 | 272.5K | 3,873,166 | — | ↗ |
| 2021-10-13 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 10,875 | 12.83 | 139.5K | 3,962,452 | — | ↗ |
| 2021-10-12 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 18,000 | 12.77 | 229.9K | 3,973,166 | — | ↗ |
| 2021-10-07 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 39,286 | 12.45 | 489.1K | 3,923,166 | — | ↗ |
| 2021-10-06 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 10,714 | 12.53 | 134.3K | 3,962,452 | — | ↗ |
| 2021-10-05 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 14,218 | 12.66 | 180.1K | 3,973,166 | — | ↗ |
| 2021-10-04 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 23,681 | 13.08 | 309.9K | 3,987,384 | — | ↗ |
| 2021-10-01 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 19,684 | 13.23 | 260.5K | 4,011,065 | — | ↗ |
| 2021-09-30 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 18,558 | 13.07 | 242.5K | 4,030,749 | — | ↗ |
| 2021-09-29 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 16,396 | 13.41 | 219.8K | 4,049,307 | — | ↗ |
| 2021-09-28 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 6,263 | 14.27 | 89.4K | 4,065,703 | — | ↗ |
| 2021-09-27 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 29,890 | 14.81 | 442.8K | 4,071,966 | — | ↗ |
| 2021-09-24 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 11,418 | 14.49 | 165.4K | 4,101,856 | — | ↗ |
| 2021-09-23 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 9,892 | 14.68 | 145.2K | 4,113,274 | — | ↗ |
| 2021-09-22 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 19,669 | 15.14 | 297.8K | 4,123,166 | — | ↗ |
| 2021-09-21 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 16,860 | 15.24 | 256.9K | 4,142,835 | — | ↗ |
| 2021-09-20 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 13,471 | 15.06 | 202.9K | 4,159,695 | — | ↗ |
| 2021-07-14 | SIMARD JOHN | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 50,000 | 18.15 | 907.4K | 4,173,166 | — | ↗ |
| 2021-07-09 | MacAdam Donald H. | Director | M-Exempt | D | Stock options | 10,000 | 4.40 | 44.0K | 2,500 | — | ↗ |
| 2021-07-09 | Libby Peter | Director | M-Exempt | A | Common Shares | 25,000 | 7.76 | 194.0K | 25,000 | — | ↗ |
| 2021-06-22 | Waldin Jan-Paul | Director | A-Award | A | Stock Option | 25,000 | 16.21 | 405.3K | 25,000 | — | ↗ |
| 2021-06-22 | MacAdam Donald H. | Director | A-Award | A | Stock Option | 25,000 | 16.21 | 405.3K | 25,000 | — | ↗ |
| 2021-06-22 | MCKENZIE W THORPE | Director / 10% Owner | A-Award | A | Stock Option | 25,000 | 16.21 | 405.3K | 25,000 | — | ↗ |
| 2021-06-22 | Libby Peter | Director | A-Award | A | Director Stock option | 25,000 | 16.21 | 405.3K | 25,000 | — | ↗ |
| 2021-03-22 | SIMARD JOHN | Director / Officer / 10% Owner | M-Exempt | A | Common Shares | 500,000 | 7.50 | 3.75M | 4,223,166 | — | ↗ |
| 2021-01-28 | SIMARD JOHN | Director / Officer / 10% Owner | W-Will | D | Stock Options | 150,000 | 7.45 | 1.12M | 150,000 | — | ↗ |
| 2020-12-18 | BAY STREET FINANCIAL S.A. | 10% Owner | S-Sale | D | Common Stock | 1,173,033 | 18.78 | 22.03M | 1,981,515 | — | ↗ |
| 2020-12-02 | BAY STREET FINANCIAL S.A. | 10% Owner | S-Sale | D | Common Stock | 182,836 | 18.42 | 3.37M | 3,154,548 | — | ↗ |
| 2020-11-19 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 375,000 | 18.30 | 6.86M | 2,560,964 | — | ↗ |
| 2020-11-06 | HU ANGELA | Officer | — | D | Employee Stock Option (right to buy) | 10,000 | 10.36 | 103.6K | 0 | — | ↗ |
| 2020-09-18 | SIMARD JOHN | Director / Officer / 10% Owner | J-Other | D | Common Stock | 500,000 | 0.00 | — | 3,723,166 | — | ↗ |
| 2020-09-15 | SHIVASWAMY SUSHMA | Officer | M-Exempt | A | Common Shares | 20,668 | 7.50 | 155.0K | 20,668 | — | ↗ |
| 2020-09-10 | SHIVASWAMY SUSHMA | Officer | M-Exempt | A | Common Shares | 19,332 | 7.50 | 145.0K | 19,332 | — | ↗ |
| 2020-09-01 | HAN QUEENA | Officer | M-Exempt | D | Stock Option | 30,000 | 4.24 | 127.2K | 0 | — | ↗ |
| 2020-08-27 | Waldin Jan-Paul | Director | A-Award | A | Stock Option | 25,000 | 18.25 | 456.3K | 25,000 | — | ↗ |
| 2020-08-27 | SIMARD JOHN | Director / Officer / 10% Owner | A-Award | A | Stock Option | 25,000 | 18.25 | 456.3K | 25,000 | — | ↗ |
| 2020-08-27 | MacAdam Donald H. | Director | A-Award | A | Stock Option | 25,000 | 18.25 | 456.3K | 25,000 | — | ↗ |
| 2020-08-27 | MCKENZIE W THORPE | Director / 10% Owner | A-Award | A | Stock Option | 25,000 | 18.25 | 456.3K | 25,000 | — | ↗ |
| 2020-08-27 | Libby Peter | Director | A-Award | A | Director Stock option | 25,000 | 18.25 | 456.3K | 25,000 | — | ↗ |
| 2020-08-24 | HAN QUEENA | Officer | M-Exempt | D | Stock Options | 3,333 | 4.14 | 13.8K | 0 | — | ↗ |
| 2020-08-17 | HAN QUEENA | Officer | M-Exempt | A | Common Shares | 1,300 | 7.50 | 9.8K | 1,300 | — | ↗ |
| 2020-02-19 | BAY STREET FINANCIAL S.A. | 10% Owner | S-Sale | D | Common Stock | 1,662,616 | 6.38 | 10.61M | 3,337,384 | — | ↗ |
| 2020-02-12 | Waldin Jan-Paul | Director | D-Return | D | Common Stock | 95,612 | 30.00 | 2.87M | 204,388 | — | ↗ |
| 2020-02-12 | SIMARD JOHN | Director / Officer / 10% Owner | D-Return | D | Common Stock | 2,016,466 | 30.00 | 60.49M | 4,310,594 | — | ↗ |
| 2020-02-12 | MCKENZIE W THORPE | Director / 10% Owner | D-Return | D | Common Stock | 15,214 | 30.00 | 456.4K | 32,524 | — | ↗ |
| 2020-02-12 | GUT THOMAS | 10% Owner | D-Return | D | Common Stock | 1,949,929 | 30.00 | 58.50M | 3,914,111 | — | ↗ |
| 2020-02-03 | RENNES FONDATION | 10% Owner | G-Gift | D | Common Stock | 5,000,000 | 0.00 | — | 110,282 | — | ↗ |
| 2020-02-03 | GUT THOMAS | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 5,864,040 | — | ↗ |
| 2020-02-03 | BAY STREET FINANCIAL S.A. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 5,000,000 | — | ↗ |
| 2020-01-06 | MCKENZIE W THORPE | Director / 10% Owner | M-Exempt | D | Stock Option | 77,000 | 3.75 | 288.8K | 1,245,500 | — | ↗ |
| 2020-01-04 | HU ANGELA | Officer | — | D | Employee Stock Option (right to buy) | 5,000 | 5.26 | 26.3K | 0 | — | ↗ |
| 2019-12-06 | SIMARD JOHN | Director / Officer / 10% Owner | M-Exempt | A | Stock Option | 1,000,000 | 11.12 | 11.12M | 2,625,000 | — | ↗ |
| 2019-11-29 | MCKENZIE W THORPE | Director / 10% Owner | M-Exempt | A | Common Stock | 185,000 | 3.75 | 693.8K | 3,583,600 | — | ↗ |
| 2019-11-06 | SHIVASWAMY SUSHMA | Officer | M-Exempt | A | Stock Option | 100,000 | 10.36 | 1.04M | 100,000 | — | ↗ |
| 2019-11-06 | HAN QUEENA | Officer | A-Award | A | Stock Option | 75,000 | 10.36 | 777.0K | 75,000 | — | ↗ |
| 2019-09-06 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 7,159 | 3.69 | 26.4K | 3,880,421 | — | ↗ |
| 2019-07-10 | Libby Peter | Director | A-Award | A | Director Stock option | 25,000 | 7.76 | 194.0K | 25,000 | — | ↗ |
| 2019-06-27 | Waldin Jan-Paul | Director | A-Award | A | Stock Option | 25,000 | 7.45 | 186.3K | 25,000 | — | ↗ |
| 2019-06-27 | SIMARD JOHN | Director / Officer / 10% Owner | M-Exempt | A | Stock Option | 300,000 | 7.45 | 2.24M | 300,000 | — | ↗ |
| 2019-06-27 | MacAdam Donald H. | Director | A-Award | A | Stock Option | 25,000 | 7.45 | 186.3K | 25,000 | — | ↗ |
| 2019-06-27 | MCKENZIE W THORPE | Director / 10% Owner | A-Award | A | Stock Option | 25,000 | 7.45 | 186.3K | 25,000 | — | ↗ |
| 2019-06-04 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 1,200,000 | 8.25 | 9.90M | 5,110,282 | — | ↗ |
| 2019-03-07 | SHIVASWAMY SUSHMA | Officer | M-Exempt | D | Stock options | 4,500 | 2.50 | 11.3K | 0 | — | ↗ |
| 2019-03-04 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 16,426 | 7.91 | 129.9K | 3,910,282 | — | ↗ |
| 2019-03-01 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 34,999 | 8.13 | 284.5K | 3,893,856 | — | ↗ |
| 2019-02-28 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 5,302 | 8.19 | 43.4K | 3,858,857 | — | ↗ |
| 2019-02-27 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 5,273 | 8.13 | 42.9K | 3,853,555 | — | ↗ |
| 2019-02-07 | SHIVASWAMY SUSHMA | Officer | M-Exempt | A | Common Stock | 4,500 | 2.50 | 11.3K | 4,500 | — | ↗ |
| 2019-02-07 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 40,000 | 10.00 | 400.0K | 3,698,282 | — | ↗ |
| 2019-02-06 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 30,000 | 9.49 | 284.7K | 3,658,282 | — | ↗ |
| 2019-01-04 | SHIVASWAMY SUSHMA | Officer | A-Award | A | Stock Option | 15,000 | 5.26 | 78.9K | 15,000 | — | ↗ |
| 2019-01-04 | HAN QUEENA | Officer | A-Award | A | Stock Option | 25,000 | 5.26 | 131.5K | 25,000 | — | ↗ |
| 2019-01-02 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 900 | 5.15 | 4.6K | 3,593,282 | — | ↗ |
| 2018-12-27 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 2,200 | 4.98 | 11.0K | 3,592,382 | — | ↗ |
| 2018-12-27 | MCKENZIE W THORPE | Director / 10% Owner | P-Purchase | A | Common Stock | 1,364 | 4.92 | 6.7K | 47,738 | — | ↗ |
| 2018-12-26 | MCKENZIE W THORPE | Director / 10% Owner | P-Purchase | A | Common Stock | 18,636 | 5.07 | 94.6K | 46,374 | — | ↗ |
| 2018-12-24 | MCKENZIE W THORPE | Director / 10% Owner | P-Purchase | A | Common Stock | 24,838 | 5.88 | 146.1K | 27,738 | — | ↗ |
| 2018-12-21 | RENNES FONDATION | 10% Owner | P-Purchase | A | Common Stock | 4,200 | 6.24 | 26.2K | 3,590,182 | — | ↗ |
| 2018-12-19 | SIMARD JOHN | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 50,000 | 2.50 | 125.0K | 6,327,060 | — | ↗ |
| 2018-11-12 | MCKENZIE W THORPE | Director / 10% Owner | P-Purchase | A | Common Stock | 700 | 3.75 | 2.6K | 2,900 | — | ↗ |
| 2018-11-09 | MCKENZIE W THORPE | Director / 10% Owner | P-Purchase | A | Common Stock | 2,200 | 3.74 | 8.2K | 2,200 | — | ↗ |
| 2018-10-04 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 385,000 | 3.00 | 1.16M | 3,398,600 | — | ↗ |
| 2018-09-26 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 17,634 | 3.05 | 53.8K | 3,783,600 | — | ↗ |
| 2018-09-13 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 7,909 | 3.10 | 24.5K | 3,801,234 | — | ↗ |
| 2018-09-12 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 41,675 | 3.06 | 127.5K | 3,809,143 | — | ↗ |
| 2018-09-10 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 23,369 | 3.22 | 75.3K | 3,850,818 | — | ↗ |
| 2018-09-07 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 6,234 | 3.65 | 22.8K | 3,874,187 | — | ↗ |
| 2018-09-05 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 7,220 | 3.94 | 28.5K | 3,887,580 | — | ↗ |
| 2018-09-04 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 3,800 | 3.99 | 15.2K | 3,894,800 | — | ↗ |
| 2018-08-10 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 3,171 | 3.98 | 12.6K | 0 | — | ↗ |
| 2018-08-09 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 6,638 | 4.00 | 26.5K | 3,171 | — | ↗ |
| 2018-08-08 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 4,000 | 4.01 | 16.0K | 121,309 | — | ↗ |
| 2018-08-07 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 8,452 | 3.94 | 33.3K | 125,309 | — | ↗ |
| 2018-08-06 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 3,340 | 3.99 | 13.3K | 133,761 | — | ↗ |
| 2018-08-03 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 23,900 | 3.96 | 94.7K | 25,601 | — | ↗ |
| 2018-08-02 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 30,461 | 3.92 | 119.5K | 49,501 | — | ↗ |
| 2018-08-01 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 8,163 | 4.24 | 34.6K | 79,962 | — | ↗ |
| 2018-07-31 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 6,531 | 4.49 | 29.3K | 88,125 | — | ↗ |
| 2018-07-30 | MCKENZIE W THORPE | Director / 10% Owner | S-Sale | D | Common Stock | 5,344 | 4.41 | 23.5K | 94,656 | — | ↗ |
| 2018-07-27 | SIMARD JOHN | Director / Officer / 10% Owner | A-Award | A | Stock Option | 15,000 | 4.26 | 63.9K | 15,000 | — | ↗ |
| 2018-06-19 | Waldin Jan-Paul | Director | A-Award | A | Stock Option | 12,500 | 4.44 | 55.5K | 12,500 | — | ↗ |
| 2018-06-19 | SIMARD JOHN | Director / Officer / 10% Owner | A-Award | A | Stock Option | 200,000 | 4.44 | 888.0K | 200,000 | — | ↗ |
| 2018-06-19 | MacAdam Donald H. | Director | A-Award | A | Stock Option | 12,500 | 4.44 | 55.5K | 12,500 | — | ↗ |
| 2018-06-19 | MCKENZIE W THORPE | Director / 10% Owner | A-Award | A | Stock Option | 25,000 | 4.44 | 111.0K | 25,000 | — | ↗ |
| 2018-06-08 | Waldin Jan-Paul | Director | — | D | Common Stock | 0 | 0.00 | — | 300,000 | — | ↗ |
| 2018-05-08 | HAN QUEENA | Officer | A-Award | A | Stock Option | 40,000 | 4.16 | 166.4K | 40,000 | — | ↗ |
| 2018-03-23 | HAN QUEENA | Officer | M-Exempt | A | Common Stock | 8,201 | 2.50 | 20.5K | 8,201 | — | ↗ |
| 2018-03-22 | HAN QUEENA | Officer | M-Exempt | A | Common Stock | 62,200 | 2.50 | 155.5K | 62,200 | — | ↗ |
| 2018-03-21 | HAN QUEENA | Officer | M-Exempt | A | Common Stock | 9,599 | 2.50 | 24.0K | 9,599 | — | ↗ |
| 2018-03-20 | MacAdam Donald H. | Director | A-Award | A | Director Stock Option | 25,000 | 4.78 | 119.5K | 25,000 | — | ↗ |
| 2018-02-27 | Waldin Jan-Paul | Director | A-Award | A | Director Stock Option | 25,000 | 4.83 | 120.8K | 25,000 | — | ↗ |
| 2017-11-20 | SHIVASWAMY SUSHMA | Officer | A-Award | A | Stock Option | 150,000 | 4.13 | 619.5K | 150,000 | — | ↗ |
| 2017-07-07 | Guzman Benjamin | Officer | A-Award | A | Employee Stock Option | 300,000 | 4.78 | 1.43M | 300,000 | — | ↗ |
| 2017-07-01 | Guzman Benjamin | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-06-19 | VASELLA DANIEL | Director | M-Exempt | A | Stock Option | 50,000 | 4.24 | 212.0K | 50,000 | — | ↗ |
| 2017-06-19 | STECHER MICHAEL | Director / Officer | M-Exempt | A | Stock Option | 50,000 | 4.24 | 212.0K | 50,000 | — | ↗ |
| 2017-06-19 | SIMARD JOHN | Director / Officer / 10% Owner | M-Exempt | A | Stock Option | 75,000 | 4.24 | 318.0K | 75,000 | — | ↗ |
| 2017-06-19 | SHIVASWAMY SUSHMA | Officer | M-Exempt | A | Stock Option | 50,000 | 4.24 | 212.0K | 50,000 | — | ↗ |
| 2017-06-19 | MCKENZIE W THORPE | Director / 10% Owner | M-Exempt | A | Stock Option | 50,000 | 4.24 | 212.0K | 50,000 | — | ↗ |
| 2017-06-19 | HAN QUEENA | Officer | M-Exempt | A | Stock Option | 30,000 | 4.24 | 127.2K | 50,000 | — | ↗ |
| 2017-06-19 | BONANNI FABRIZIO | Director | M-Exempt | A | Stock Option | 50,000 | 4.24 | 212.0K | 50,000 | — | ↗ |
| 2017-05-24 | SIMARD JOHN | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 240,000 | 0.93 | 223.6K | 6,393,267 | — | ↗ |
| 2016-12-01 | VASELLA DANIEL | Director | A-Award | A | Stock Option | 125,000 | 15.00 | 1.88M | 125,000 | — | ↗ |
| 2016-11-15 | HAN QUEENA | Officer | M-Exempt | A | Common Shares | 19,573 | 0.74 | 14.5K | 19,573 | — | ↗ |
| 2016-09-14 | VASELLA DANIEL | Director | M-Exempt | A | Stock Option | 50,000 | 13.26 | 663.0K | 50,000 | — | ↗ |
| 2016-09-14 | MCKENZIE W THORPE | Director / 10% Owner | M-Exempt | A | Stock Option | 50,000 | 13.26 | 663.0K | 50,000 | — | ↗ |
| 2016-09-14 | BONANNI FABRIZIO | Director | M-Exempt | A | Stock Option | 50,000 | 13.26 | 663.0K | 50,000 | — | ↗ |
| 2016-09-08 | HAN QUEENA | Officer | M-Exempt | A | Common Shares | 427 | 0.77 | 328.79 | 427 | — | ↗ |
| 2016-08-12 | Choudhury Kalidip | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-08-12 | Benson Trey | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-06-20 | Benson Trey | Officer | A-Award | A | Stock options | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2016-05-26 | MCKENZIE W THORPE | Director / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-05-20 | MCKENZIE W THORPE | Director / 10% Owner | P-Purchase | A | Common Stock | 750 | 13.72 | 10.3K | 5,750 | — | ↗ |
| 2016-05-16 | McCollough Dawn | Officer | A-Award | A | Stock Options | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2016-05-02 | Whitehurst James Scott | Officer | A-Award | A | Stock Option | 300,000 | 12.99 | 3.90M | 300,000 | — | ↗ |
| 2016-04-01 | HU ANGELA | Officer | — | D | Employee Stock Option (right to buy) | 4,500 | 19.00 | 85.5K | 0 | — | ↗ |
| 2016-03-31 | SIMARD JOHN | Director / Officer / 10% Owner | M-Exempt | A | Stock Option | 50,000 | 9.45 | 472.5K | 50,000 | — | ↗ |
| 2016-03-17 | SIMARD JOHN | Director / 10% Owner | O-OutOfTheMoney | D | Common Shares | 500,000 | 10.00 | 5.00M | 6,153,267 | — | ↗ |
| 2016-03-17 | MCKENZIE W THORPE | Director / 10% Owner | O-OutOfTheMoney | A | Common Shares | 500,000 | 10.00 | 5.00M | 3,898,600 | — | ↗ |
| 2016-03-01 | VASELLA DANIEL | Director | M-Exempt | A | Stock Option | 125,000 | 7.79 | 973.8K | 125,000 | — | ↗ |
| 2016-03-01 | MCKENZIE W THORPE | Director / 10% Owner | M-Exempt | A | Stock Option | 15,000 | 7.79 | 116.9K | 15,000 | — | ↗ |
| 2016-03-01 | BONANNI FABRIZIO | Director | M-Exempt | A | Stock Option | 33,333 | 7.79 | 259.7K | 33,333 | — | ↗ |
| 2015-12-22 | HAN QUEENA | Officer | M-Exempt | A | Common Shares | 10,000 | 0.72 | 7.2K | 10,000 | — | ↗ |
| 2015-12-21 | HAN QUEENA | Officer | S-Sale | D | Common Shares | 7,110 | 10.11 | 71.9K | 2,890 | — | ↗ |
| 2015-12-18 | HAN QUEENA | Officer | S-Sale | D | Common Shares | 7,700 | 10.51 | 80.9K | 2,300 | — | ↗ |
| 2015-12-16 | HAN QUEENA | Officer | M-Exempt | D | Stock Option | 10,000 | 0.72 | 7.2K | 40,000 | — | ↗ |
| 2015-12-14 | Choudhury Kalidip | Officer | M-Exempt | A | Stock options | 50,000 | 7.71 | 385.5K | 50,000 | — | ↗ |
| 2015-11-25 | MCKENZIE W THORPE | Director / 10% Owner | G-Gift | D | Common Shares | 18,400 | 0.00 | — | 3,398,600 | — | ↗ |
| 2015-11-16 | STECHER MICHAEL | Director / Officer | M-Exempt | D | Stock Option | 1,800 | 5.00 | 9.0K | 58,200 | — | ↗ |
| 2015-06-08 | THORNBURG KELLY | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-04-14 | VASELLA DANIEL | Director | — | D | Common Stock | 0 | 0.00 | — | 30,000 | — | ↗ |
| 2015-04-14 | STECHER MICHAEL | Director / Officer | — | D | Stock Option | 15,000 | 15.00 | 225.0K | 0 | — | ↗ |
| 2015-04-14 | SIMARD JOHN | Director / Officer / 10% Owner | — | D | Stock Option | 500,000 | 10.00 | 5.00M | 0 | — | ↗ |
| 2015-04-14 | SHIVASWAMY SUSHMA | Officer | — | D | Stock Option | 30,000 | 15.00 | 450.0K | 0 | — | ↗ |
| 2015-04-14 | MCKENZIE W THORPE | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2015-04-14 | GONZALEZ NORMA I | Officer | — | D | Stock Option | 2,000 | 15.00 | 30.0K | 0 | — | ↗ |
| 2015-04-14 | COMBS DAVID J | Officer | — | D | Stock Option | 15,000 | 15.00 | 225.0K | 0 | — | ↗ |
| 2015-01-01 | MCKENZIE W THORPE | Director / 10% Owner | — | D | Stock Option | 15,000 | 15.00 | 225.0K | 0 | — | ↗ |
| 2014-11-04 | VASELLA DANIEL | Director | — | D | Stock Option | 125,000 | 15.00 | 1.88M | 0 | — | ↗ |
| 2014-08-24 | BONANNI FABRIZIO | Director | — | D | Stock Option | 33,333 | 15.00 | 500.0K | 0 | — | ↗ |
| 2014-03-01 | SIMARD JOHN | Director / Officer / 10% Owner | — | D | Option to Sell | 500,000 | 10.00 | 5.00M | 0 | — | ↗ |
| 2014-03-01 | MCKENZIE W THORPE | Director / 10% Owner | — | D | Stock Option | 500,000 | 10.00 | 5.00M | 0 | — | ↗ |
| 2014-03-01 | BONANNI FABRIZIO | Director | — | D | Stock Option | 33,333 | 10.00 | 333.3K | 0 | — | ↗ |
| 2012-12-12 | HAN QUEENA | Officer | — | D | Stock Option | 5,000 | 15.00 | 75.0K | 0 | — | ↗ |
| 2011-12-31 | MCKENZIE W THORPE | Director / 10% Owner | — | D | Stock Option | 250,000 | 10.00 | 2.50M | 0 | — | ↗ |
| 2011-04-12 | SIMARD JOHN | Director / Officer / 10% Owner | — | D | Stock Option | 500,000 | 7.50 | 3.75M | 0 | — | ↗ |
| 2011-02-28 | SHIVASWAMY SUSHMA | Officer | — | D | Stock Option | 40,000 | 7.50 | 300.0K | 0 | — | ↗ |
| 2011-02-28 | HAN QUEENA | Officer | — | D | Stock Option | 20,000 | 7.50 | 150.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
30.49M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | John Simard, President & Chief Executive Officer | 1.21M | 5.03M | — | — | — | 10.5K | 6.25M | 0.00% | ↗ |
| 2 | 2024 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | 450.0K | 197.0K | — | — | — | 10.5K | 657.6K | 0.00% | ↗ |
| 3 | 2024 | Angela Hu, Director of Finance | 200.0K | 80.0K | — | — | — | 5.4K | 285.4K | 0.00% | ↗ |
| 4 | 2023 | John Simard, President Chief Executive Officer | 1.07M | 4.48M | — | — | — | 11.0K | 5.56M | 0.00% | ↗ |
| 5 | 2023 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | 445.2K | — | — | 270.5K | — | 4.8K | 720.5K | 37.54% | ↗ |
| 6 | 2023 | Angela Hu, Director of Finance | 193.3K | — | — | 81.2K | — | 4.8K | 279.3K | 29.06% | ↗ |
| 7 | 2022 | John Simard, President Chief Executive Officer | 881.4K | 3.78M | — | — | — | 9.5K | 4.67M | 0.00% | ↗ |
| 8 | 2022 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | 376.4K | — | — | — | — | 4.8K | 381.2K | 0.00% | ↗ |
| 9 | 2022 | Queena Han, Vice President Finance HR and Secretary | 322.8K | — | — | — | — | 9.5K | 332.3K | 0.00% | ↗ |
| 10 | 2021 | John Simard, President Chief Executive Officer | 776.6K | 7.00M | — | — | — | 9.0K | 7.79M | 0.00% | ↗ |
| 11 | 2021 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | 376.4K | 187.5K | — | 875.1K | — | 4.8K | 1.44M | 60.61% | ↗ |
| 12 | 2021 | Queena Han, Vice President Finance HR | 321.1K | 159.8K | — | 306.3K | — | 9.0K | 796.2K | 38.47% | ↗ |
| 13 | 2020 | John Simard President Chief Executive Officer | 683.7K | 2.73M | — | — | — | 10.1K | 11.94M | 0.00% | ↗ |
| 14 | 2020 | John Simard, President Chief Executive Officer | 683.7K | 2.73M | — | — | — | 10.1K | 3.42M | 0.00% | ↗ |
| 15 | 2020 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | 300.0K | 150.0K | — | — | — | 6.2K | 864.5K | 0.00% | ↗ |
| 16 | 2020 | Queena Han Vice President Finance HR | 298.8K | 50.0K | — | — | — | 9.4K | 622.0K | 0.00% | ↗ |
| 17 | 2020 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | 300.0K | 150.0K | — | — | — | 6.2K | 456.2K | 0.00% | ↗ |
| 18 | 2020 | Queena Han, Vice President Finance HR | 298.8K | 50.0K | — | — | — | 9.4K | 358.3K | 0.00% | ↗ |
| 19 | 2019 | John Simard President Chief Executive Officer | 590.9K | 228.0K | — | — | — | 9.0K | 10.81M | 0.00% | ↗ |
| 20 | 2019 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | 300.0K | 300.0K | — | — | — | 6.2K | 1.43M | 0.00% | ↗ |
| 21 | 2019 | Queena Han Vice President Finance HR | 200.0K | 200.0K | — | — | — | 9.0K | 1.07M | 0.00% | ↗ |
| 22 | 2018 | John Simard President Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 23 | 2018 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 24 | 2018 | Queena Han Vice President Finance HR | — | — | — | — | — | — | — | — | ↗ |
| 25 | 2017 | John Simard President Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 26 | 2017 | Queena Han Vice President Finance HR | — | — | — | — | — | — | — | — | ↗ |
| 27 | 2017 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 28 | 2017 | Michael Stecher, M.D. Medical Director | — | — | — | — | — | — | — | — | ↗ |
| 29 | 2016 | Kelly Thornburg Senior Vice President of Operations | 315.0K | 35.6K | — | — | — | 7.4K | 677.0K | 0.00% | ↗ |
| 30 | 2016 | John Simard President Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 31 | 2016 | Michael Stecher, M.D. Medical Director | — | — | — | — | — | — | — | — | ↗ |
| 32 | 2016 | Sushma Shivaswamy, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 33 | 2015 | John Simard President Chief Executive Officer | 551.4K | 550.0K | — | — | — | 6.8K | 2.32M | 0.00% | ↗ |
| 34 | 2015 | Michael Stecher, M.D. Medical Director | 279.0K | 218.0K | — | — | — | 6.8K | 575.5K | 0.00% | ↗ |
| 35 | 2015 | Kelly Thornburg Senior Vice President of Operations | 177.9K | — | — | — | — | 78.1K | 423.8K | 0.00% | ↗ |
| 36 | 2014 | John Simard President Chief Executive Officer | 551.4K | — | — | — | — | 6.0K | 1.48M | 0.00% | ↗ |
| 37 | 2014 | Michael Stecher, M.D. Medical Director | 241.4K | — | — | — | — | 6.0K | 258.5K | 0.00% | ↗ |
| 38 | 2014 | Kelly Thornburg Senior Vice President of Operations | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Simard | Founder & Chairman | 27M | male |
| Sushma Shivaswamy | Interim CEO & Chief Scientific Officer | 571.0K | — |
| Angela Hu | Director of Finance | 245.4K | female |
| Qian Wu | Senior Vice President of Clinical Operations & Analytical Quality | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XBIT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
